Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from Central Poland;Polimorfizm genu manganowej dysmutazy ponadtlenkowej (MnSOD) u pacjentów z centralnej Polski z objawami późnych dyskinez w przebiegu schizofrenii

Psychiatria Polska

Volumn 40, Issue 5, 2006, Pages 937-948

  Gałecki, Piotr ^a   Pietras, Tadeusz ^b   Szemraj, Janusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Medical University of Lodz Klinika Pneumonologii i Alergologii   (Poland)

Author keywords

Manganese superoxide dismutase; Schizophrenia; Tardive dyskinesia

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PATIENT PARTICIPATION; POLAND; POSITIVE AND NEGATIVE SYNDROME SCALE; SCORING SYSTEM; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COMORBIDITY; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLAND; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE; VARIATION (GENETICS);

EID: 33751113892     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry 2000; 61: 15-20.
2. Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K. Tardive dyskinesia and ethnicity: review of the literature. Ann. Clin. Psychiatry 1997; 9: 53-59.
3. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiatry 2000; 61: 5-9.
4. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry 1998; 155: 1207-1213.
5. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-2406.
6. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-Dopa-induced dyskinesias, neuroleptic-induced sensitivity psychosis and refractory schizophrenia. Biol. Psychiatry 1993; 34: 713-738.
7. Schadev PS. The current status of tardive dyskinesia. Aust. N. Z. J. Psychiatry 2000; 34: 355-369.
8. Kuloglu M, Ustundag B, Atmaca M. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell. Biochem. Funct. 2002; 20: 171-175.
9. Petronijevic ND, Micic DV, Duricic B. Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in schizophrenia. Progr. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 431-440.
10. Srivastava N, Barthwal MK, Dalal PK. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacol. 2001; 158: 140-145.
11. Akyol O, Herken H, Uz E. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Progr. Neuropharmacol. Biol. Psychiatry 2002; 26: 995-1005.
12. Yao JK, Reddy R, McElhinny LG. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998; 32: 385-391.
13. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346: 552-557.
14. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992; 59: 1609-1623.
15. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: A comparison of the Cu,ZnSOD (sod1), MnSOD (sod2), and EC-SOD (sod3) gene structures, evolution, and expression. Free Radic. Biol. Med. 2002; 33: 337-349.
16. Church SL, Grant JW, Meese EU, Trent JM. Sublocalization of the gene encoding manganese superoxide dismutase(MnSOD/SOD2) to 6q25 by fluorescence in situ hybridization and somatic cell hybrid mapping. 1992; 14: 823-825.
17. Modlin SO, Gottesman II. At issue: genes, experience, and chance in schizophrenia-positioning for the 21st century. Schizophr. Bull. 1997; 23: 547-561.
18. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem. Biophys. Res. Commun. 1996; 226: 561-565.
19. Borgstahl GEO, Parge HE, Hickey MJ, Johnson MJ, Boissinot M, Hallewell RA. Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destablising the tetrameric interface. Biocemistry 1996; 43: 863-867.
20. Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet. 1997; 60: 588-596.
21. Lemire BD, Fankhauser C, Baker A, Schatz G. The mitochondrial targeting function of randomly generated peptide sequences correlates with predicted helical amphiphilicity. J. Biol. Chem. 1989; 264: 20206-20215.
22. Shimoda-Matsubayashi S, Hattori T, Matsumine H, Shinohara A, Yorikata A, Mori H, Kondo T. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurol. 1997; 49: 1257-1261.
23. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Opisy kliniczne i wskazówki diagnostyczne. Kraków: Uniwersyteckie Wydawnictwo Medyczne "Vesalius"; 1997.
24. Kay SR, Opler LA. Positive and Negative Syndrome Scale (PANSS) rating manual. San Rafael CA: Social and Behavioral Sciences Documents; 1987.
25. Simpson GH, Angus JW. A rating scale for extrapiramidal side effect. Acta Psychiatr. Scand. 1970; 212: 11-19.
26. Svejgaard I. HLA and disease, 1982 - a survey. Immunol. Rev. 1983; 70: 193.
27. Sambrook J, Russell DW. Molecular cloning. A laboratory manual. Cold Spring Halbor, New York, USA: Cold Spring Harbor Laboratory Press; 2001.
28. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur. Psychiatry 2004; 19: 326-337.
29. Valencia A, Moran J. Reactive oxygen species induce different cell death mechanism in cultured neurons. Free Rad Biol Med. 2004; 36: 1112-1125.
30. Kahl R, Kampkotter A, Watjen W, Chovolou Y. Antioxidant enzymes and apoptosis. Drug Metabol. Rev. 2004; 36: 747-762.
31. Michell TM, Thome J, Martin D, Nara K, Zwerina S, Koutsilieri E. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J. Neural. Transm. 2004; 111: 1191-201.
32. Gałecki P, Nowakowski T. Trace elements (copper, zinc) content and superoxide dismutase activity in erythrocytes from schizophrenic patients. Acta Psychiatr. Scand. 2004 (supl.); 421: 14.
33. Hori H, Ohmori O, Shinakai T, Kojima H, Okano C, Suzuki T, Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacol. 2000; 23: 170-176.
34. Zhang ZJ, Zhang XB, Hou G, Sha WW, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J. Psychiatr. Res. 2002; 26: 317-324.
35. Akyol O, Yanik M, Elyas H, Namli M, Cnatan H, Zoroglu SS. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 2005; 29: 123-131.
36. Jeste DV, Lohr JB, Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacol. 1992; 106: 154-160.
37. Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 2004; 55: 676-684.
38. Prince JA, Yassin MS, Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J. Pharmacol. Exp. Ther. 1997; 280: 261-267.
39. Di Monte DA, McCormack A, Petzinger G, Janson AM, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 2000; 15: 459-466.
40. Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol. J. Pharmacol. 2002; 54: 299-312.
41. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry 1982; 37: 473-481.
42. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 1992; 18: 701-715.
43. Pietras T. Udział nieprawidłowej czynności łańcucha oddechowego mitochondriów w patogenezie schizofrenii. Post. Psychiatr. Neurol. 2004; 13: 135-144.
44. Joseph J, Denisova N, Strain J. Oxidative stress and age related neuronal deficits. Mol. Chem. Neuropath. 1996; 28: 35-40.